Advertisement
Advertisement

REGN

REGN logo

Regeneron Pharmaceuticals Inc

609.94
USD
Sponsored
+2.01
+0.33%
Jun 18, 16:00 UTC -4
Closed
exchange

After-Market

607.02

-2.92
-0.48%

REGN Earnings Reports

Positive Surprise Ratio

REGN beat 34 of 41 last estimates.

83%

Next Report

Date of Next Report
Jul 30, 2026
Estimate for Q2 26 (Revenue/ EPS)
$3.91B
/
$11.06
Implied change from Q1 26 (Revenue/ EPS)
+8.37%
/
+16.79%
Implied change from Q2 25 (Revenue/ EPS)
+6.30%
/
-14.20%

Regeneron Pharmaceuticals Inc earnings per share and revenue

On Apr 29, 2026, REGN reported earnings of 9.47 USD per share (EPS) for Q1 26, beating the estimate of 9.11 USD, resulting in a 3.88% surprise. Revenue reached 3.61 billion, compared to an expected 3.56 billion, with a 1.38% difference. The market reacted with a -6.21% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 11 analysts forecast an EPS of 11.06 USD, with revenue projected to reach 3.91 billion USD, implying an increase of 16.79% EPS, and increase of 8.37% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
logo
Prenetics Global Limited Class A Ordinary Share
Report Date
Jun 10, 2026 For Q1 26
Estimate
-$1.10
Actual
-$1.61
Surprise
-45.36%
logo
Anixa Biosciences, Inc.
Report Date
Jun 10, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+21.61%
logo
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
FAQ
For Q1 2026, Regeneron Pharmaceuticals Inc reported EPS of $9.47, beating estimates by 3.88%, and revenue of $3.61B, 1.38% above expectations.
The stock price moved down -6.21%, changed from $731.77 before the earnings release to $686.36 the day after.
The next earning report is scheduled for Jul 30, 2026.
Based on 11 analysts, Regeneron Pharmaceuticals Inc is expected to report EPS of $11.06 and revenue of $3.91B for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement